Document is current
Any future updates will be listed below
-
Authors
Michaeli, Julia Caroline https://orcid.org/0000-0001-6484-7161
Michaeli, Thomas https://orcid.org/0000-0003-0293-9401
Trapani, Dario https://orcid.org/0000-0003-1672-9560
Albers, Sebastian https://orcid.org/0000-0002-6688-764X
Dannehl, Dominik https://orcid.org/0000-0002-7653-8283
Würstlein, Rachel
Michaeli, Daniel Tobias https://orcid.org/0000-0003-2913-1867
-
Funding
Funding for this research was provided by:
Universitätsklinikum Heidelberg
- License Information
-
More Information
Article History
Received: 25 February 2024
Accepted: 15 September 2024
First Online: 25 September 2024
Declarations
:
: Rachel Würstlein disclosed the following conflicts of interests: Agendia, Amgen, APOGHEVA, Aristo, Astra Zeneca, Celgene, Clovis Oncology, Daiichi-Sankyo, Eisai, Esteve, Exact Sciences, Gilead, Glaxo Smith Kline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Mylan, Nanostring, Novartis, Odonate, Onkowissen, Paxman, Palleos, Pfizer, Pierre Fabre, PINK, PumaBiotechnolgogy, Riemser, Roche, Sandoz/Hexal, Sanofi Genzyme, Seattle Genetics /Seagen, Sidekick, Stemline, Tesaro Bio, Teva, Veracyte, Viatris, Wilex, SPCC, FOMF, Aurikamed, Clinsol, PommeMed, iMED Institutmedconcept, MCI, MediSeminar, Medicultus. The other authors declare that they have no conflict of interest.
: Not applicable.
: None needed.
: Not commissioned; externally peer-reviewed.
: No patients were involved in the conduct of this study.
